Mississippi Senate Bill SB2025

Mississippi 2026 Regular Session

• Introduced: 1/8/26
• Refer: 1/8/26
• Failed: 2/3/26

Caption

AN ACT TO PROVIDE THAT THE DIVISION OF MEDICAID, IN ESTABLISHING AND MAINTAINING THE PREFERRED DRUG LIST, SHALL ENSURE THAT NO NONOPIOID DRUG APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OR MANAGEMENT OF PAIN SHALL BE DISADVANTAGED OR DISCOURAGED WITH RESPECT TO COVERAGE RELATIVE TO ANY OPIOID OR NARCOTIC DRUG FOR THE TREATMENT OR MANAGEMENT OF PAIN ON SUCH PREFERRED DRUG LIST; TO REQUIRE THAT ANY HEALTH INSURANCE INSURER OFFERING A HEALTH INSURANCE POLICY OR HEALTH BENEFIT PLAN DEVELOP A PLAN TO PROVIDE ADEQUATE COVERAGE AND ACCESS TO A BROAD SPECTRUM OF PAIN MANAGEMENT SERVICES THAT SERVE AS ALTERNATIVES TO THE PRESCRIBING OF OPIOID DRUGS; TO REQUIRE SUCH AN INSURER TO FILE THE PLAN WITH THE DEPARTMENT OF INSURANCE FOR APPROVAL; TO PROVIDE THAT SUCH AN INSURER SHALL ANNUALLY DISTRIBUTE EDUCATIONAL MATERIALS TO PROVIDERS WITHIN ITS NETWORK AND TO MEMBERS ABOUT THE PAIN MANAGEMENT ACCESS PLAN AND SHALL MAKE INFORMATION ABOUT ITS PLAN PUBLICLY AVAILABLE ON ITS WEBSITE; AND FOR RELATED PURPOSES.

Impact

The bill is intended to address the growing opioid crisis by promoting alternative pain management treatments. By ensuring that nonopioid options are readily accessible and adequately covered, SB2025 seeks to shift the focus of pain management away from opioids, thereby potentially decreasing dependency on these substances. Insurers will also be mandated to file their coverage plans with the Department of Insurance to ensure compliance with these requirements, creating a regulatory framework that promotes fair treatment of nonopioid medications.

Summary

Senate Bill 2025 establishes new provisions aimed at ensuring that nonopioid medications are treated equally to opioid medications in terms of coverage by Medicaid and health insurance insurers. The bill mandates that the Division of Medicaid cannot disadvantage or discourage the use of nonopioid drugs approved by the FDA for pain management when compared to opioid drugs on the preferred drug list. Additionally, it requires insurers to develop comprehensive coverage plans that include a variety of pain management services, including nonpharmacologic options.

Contention

Notably, there have been discussions around the potential implications of this bill on the pharmaceutical industry and public health. Proponents argue that the bill will expand patient choices and reduce the risk of addiction associated with opioids. However, some critics express concerns over the practical implementation of such mandates and the readiness of the healthcare system to adopt these changes by the effective date of July 1, 2026. Questions remain about how adequately insurers will adhere to the requirements without over-regulating access to alternative treatments.